Alterity Therapeutics Limited (FRA:PBN)
Germany · Delayed Price · Currency is EUR | Market Cap | 60.41M +28.1% |
| Revenue (ttm) | 3.77M +78.2% |
| Net Income | -8.29M |
| EPS | -0.05 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.2000 |
| Previous Close | 0.2000 |
| Day's Range | 0.2000 - 0.2000 |
| 52-Week Range | 0.1000 - 0.5000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Alterity Therapeutics
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as we... [Read more]
Financial Performance
In fiscal year 2025, Alterity Therapeutics's revenue was 5.44 million, an increase of 35.32% compared to the previous year's 4.02 million. Losses were -12.15 million, -36.48% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patie...
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing d...
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for E...
Alterity Therapeutics Earnings release: Q3 2026
Alterity Therapeutics released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Alterity Therapeutics Transcript: KOL event
ATH434 demonstrated up to 48% slowing of MSA progression in phase II with a strong safety profile, supported by robust biomarker and imaging data. The upcoming phase III trial will use a 50 mg dose, rigorous patient selection, and validated endpoints, with regulatory alignment and key catalysts expected in 2026.
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previou...
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
Alterity Therapeutics Transcript: NWR Virtual Healthcare Conference
ATH434 demonstrated robust efficacy in phase II for MSA, showing significant slowing of disease progression and strong safety. Commercial potential is high, with peak sales estimated at $2.4 billion and broad neurologist support. Phase III is planned globally, with key milestones expected this year.
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –
Alterity Therapeutics Quarterly report: H1 2026
Alterity Therapeutics has published its H1 2026 quarterly earnings report on February 24, 2026.
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and mult...
Alterity Therapeutics Transcript: Bell Potter Healthcare Conference 2025
Phase II results showed ATH-434 significantly slowed MSA progression with strong safety and robust commercial potential. FDA meetings are planned for early next year, with phase III preparations underway and IP protections being strengthened.
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced...
Alterity Therapeutics Earnings release: Q1 2026
Alterity Therapeutics released its Q1 2026 earnings on October 31, 2025, summarizing the period's financial results.
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging ...
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Transcript: Biotech Showcase
A major biotech showcase drew hundreds of investors and industry leaders, spotlighting advances in cell therapies and neurodegenerative disease treatments. Key presentations included positive Phase II results for an oral therapy for multiple system atrophy, with plans for Phase III and recent capital raised.
Alterity Therapeutics to Present at the Biotech Showcase
MELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Annual report: H2 2025
Alterity Therapeutics has published its H2 2025 annual report on August 29, 2025.